-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Adaptimmune Therapeutics PLC quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from 2013 to 2023.
- Adaptimmune Therapeutics PLC Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was $69.5M.
- Adaptimmune Therapeutics PLC Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was -$72.5M, a 20.4% increase year-over-year.
- Adaptimmune Therapeutics PLC annual Net Income (Loss) Attributable to Parent for 2023 was -$114M, a 31.2% increase from 2022.
- Adaptimmune Therapeutics PLC annual Net Income (Loss) Attributable to Parent for 2022 was -$165M, a 4.66% decline from 2021.
- Adaptimmune Therapeutics PLC annual Net Income (Loss) Attributable to Parent for 2021 was -$158M, a 21.5% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Growth (%)